Concr
Predict cancer treatment benefit for every patient
About Concr
Concr is a London-based TechBio company developing AI-powered predictive models that help researchers and clinicians understand how individual cancer patients are likely to respond to specific therapies.
Its proprietary FarrSight® platform combines Bayesian AI with computational techniques originally developed for astrophysics to analyze multimodal clinical, genomic and imaging data, enabling more accurate treatment-response prediction even with relatively small datasets. The platform is designed to improve precision oncology, accelerate biomarker discovery, and support better clinical trial design for new cancer therapies.
The company collaborates with leading pharmaceutical companies, cancer research organizations and healthcare institutions, including Roche, Debiopharm, Step Pharma, The Institute of Cancer Research, The Christie NHS Foundation Trust, Durham University, and The University of Queensland.
Concr’s technology is being applied across therapeutic development, clinical trial simulation, and personalized treatment selection, with ongoing clinical validation through studies such as the AI-VISION breast cancer program.
Founders
Funding History
Frequently Asked Questions
What does Concr do?
Concr is a TechBio company developing Bayesian AI models that predict patient responses to cancer therapies using multimodal clinical, imaging and molecular data. Its platform helps improve drug development, precision medicine and clinical trial design.
When was Concr founded?
Concr was founded in 2018 and is headquartered in London, England, with an Australian subsidiary supporting research collaborations.
Who founded Concr?
Concr was founded by Matthew Foster, Dr. Matthew Griffiths and Dr. Uzma Asghar.
How much funding has Concr raised?
Concr has publicly announced approximately £3.12 million in funding, including about £2.32 million in equity financing across multiple Seed rounds and an £800,000 non-dilutive Innovate UK grant.
Who are Concr's investors?
Publicly disclosed investors include R42 Group, Cambridge Enterprise Ventures, Oncology Ventures, SyndicateRoom, Debiopharm Innovation Fund, Jo Pisani (Cambridge Angels), Parkwalk Advisors and Avonmore Developments. The company has also received funding from Innovate UK.
What is Concr's latest funding round?
The latest announced financing is an £800,000 Innovate UK non-dilutive grant awarded on 12 February 2024 to support the AI-VISION clinical study in triple-negative breast cancer.
What is Concr's valuation?
Concr has not publicly disclosed its valuation in any of its announced funding rounds.
